SCHEMBL23977202

SCHEMBL23977202

C=CCCC(O)c1c(I)ccnc1Cl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30060673 1.00
SCHEMBL23977203 0.85
SCHEMBL23976762 0.71 FFAR1 (0.34)
SCHEMBL30060664 0.71 FFAR1 (0.34)
SCHEMBL28895831 0.69 TTR (0.32)
SCHEMBL31062502 0.68 KDM4E (0.30)
SCHEMBL23987331 0.68
SCHEMBL2113347 0.67
SCHEMBL25613938 0.67 CCNB2 (0.36)
SCHEMBL31484455 0.64 SMN1; SMN2 (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12226405-B2 Compounds and compositions for inhibiting the activity of HIF2-alpha and their methods of use NOVARTIS AG (CH) 2025-02-18 US disclosed
EP-4143187-B1 COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2-ALPHA AND THEIR METHODS OF USE NOVARTIS AG (CH) 2024-05-08 EP disclosed
EP-4143187-A1 COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2-ALPHA AND THEIR METHODS OF USE Novartis AG (CH) 2023-03-08 EP disclosed
US-20220401422-A1 COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2-alpha AND THEIR METHODS OF USE NOVARTIS AG (CH) 2022-12-22 US disclosed
US-20220401422-A1 COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2-alpha AND THEIR METHODS OF USE NOVARTIS AG (CH) 2022-12-22 US disclosed
CN-115485275-A Compounds and compositions that inhibit HIF 2-alpha activity and methods of use thereof 诺华股份有限公司 2022-12-16 CN disclosed
WO-2021220170-A1 COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2-ALPHA AND THEIR METHODS OF USE NOVARTIS AG (CH) 2021-11-04 WO disclosed
WO-2021217508-A1 COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2α AND THEIR METHODS OF USE NOVARTIS AG (CH) 2021-11-04 WO disclosed